Navigation Links
SGX Initiates Phase I Trials for SGX523
Date:1/16/2008

than 200 protein kinases and has demonstrated both potent in vitro blockage of the activity of this cancer target and in vivo activity against various types of human cancer cells that depend on cMET for their uncontrolled growth and proliferation. The cMET receptor tyrosine kinase has been implicated in a wide range of cancers, including both solid and blood tumors. cMET has been extensively studied in the laboratory environment and, to a lesser extent, in the clinic, with increasing data suggesting that uncontrolled stimulation of cMET plays a key role in a variety of effects associated with cancer, including cellular growth, increased cell movement and invasion, and an increased ability of cancer cells to metastasize. Other observations have implicated cMET in increased angiogenesis. cMET activation has been observed in a wide range of other cancer types including breast, colon, prostate, pancreatic and gastric cancers.

About SGX Pharmaceuticals

SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The SGX oncology pipeline includes drug candidates from its FAST(TM) drug discovery platform, such as next generation BCR-ABL inhibitors being developed by SGX and in partnership with Novartis and cMET tyrosine kinase inhibitors, including SGX523, and JAK2 inhibitors. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, the potential of SGX523 as a treatment for certain cancers, the potential outcome of Phase I clinical studies of SGX523, the role of cMET in cancer, statements regarding bringin
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
2. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
3. Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
4. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
5. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
6. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
7. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
8. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
9. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
10. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
11. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Electrophysiologist Kevin Makati, M.D. with St. ... Boston, MA to speak about ... Society conference. These scientific sessions drew more than ... people and technology that propel their specialty forward. ... invasive cardiac operation that combines the expertise of ...
(Date:5/22/2015)... 2015 The North American dental lasers ... estimated to reach $90.7 million by 2019, at a CAGR ... the TOC of North America Dental Lasers Market for an ... various tables and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ... report.   Dental lasers are specifically used ...
(Date:5/22/2015)...  The U.S. Food and Drug Administration,s (FDA) ... biosimilar product approved in the United ... the contract manufacturing organization (CMO) industry, according to ... to the production of small-molecular drugs and lacks ... healthcare market research publisher,s report, Biopharmaceutical and ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
... Columbia Laboratories, Inc. (Nasdaq: CBRX ), ... today confirmed that the Advisory Committee for Reproductive Health ... is scheduled to review Columbia,s New Drug Application (NDA) ... of preterm birth in women with short uterine cervical ...
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... been named to the role of Executive Vice President ... employment with Valeant, which is expected to be December ... Sachs where he was the chief operating officer for ...
Cached Medicine Technology:Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 2Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 3Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 4Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer 2Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer 3
(Date:5/26/2015)... (PRWEB) May 26, 2015 Many ... added to TheCelebrityDresses.com's formal dress collections recently. Now, ... newly designed dresses, up to 70% off. The ... the world to save hundreds of dollars on ... well-known brand in red carpet fashion special occasion ...
(Date:5/26/2015)... U.S. Food and Drug Administration (FDA) ... are extensive and can be difficult to understand. ... device companies comply with FDA regulations, compiled a list ... FDA requirements. , 1. Start researching early. ... be a lengthy process depending on the classification of ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Carl W. ... Pinehurst Surgical Center in Pinehurst, N.C. have launched a ... surgery patients about chronic sinusitis and the benefits of ... can be used to determine if someone is a ... about symptoms and other factors that can contribute to ...
(Date:5/25/2015)... (PRWEB) May 26, 2015 The ... Hooker as a 2015-2016 inductee into its VIP Professional ... this prestigious distinction for leadership in dentistry. NAPW is ... boasting more than 700,000 members and over 200 operating ... into this exceptional group of professional women,” said NAPW ...
(Date:5/25/2015)... May 25, 2015 World Patent Marketing, ... announces the Hidee-Hose, an undergarment patent that allays women’s ... Global Women's Hosiery industry forecasts the market to reach ... and Creative Director of World Patent Marketing , ... steering ahead and is expected to maintain its lead. ...
Breaking Medicine News(10 mins):Health News:Cocktail Dresses Inspired by Celebrities on Sale at TheCelebrityDresses.com 2Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 2Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 3Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 4Health News:Pinehurst Surgical Sinus Center Launches Pinehurst Balloon Sinuplasty Website 2Health News:National Association of Professional Women Inducts Dr. Laquinas Hooked, D.D.S. of General Dentist, Into its VIP Professional Woman of the Year Circle 2Health News:For The Courtesy Of Women's Health And Looks - World Patent Marketing Presents A New Undergarment Patent 2Health News:For The Courtesy Of Women's Health And Looks - World Patent Marketing Presents A New Undergarment Patent 3
... Singapore might be prosperous. But it is also draconian. Any presumed ... ,,As the owner of a commercial fishing pond in Pasir Ris ... for breeding mosquitoes. The area is dubbed the number one dengue ... of Wednesday. ,The National Environment Agency (NEA) believes ...
... that the combined use of two minimally invasive techniquesendobronchial ... the diagnosis of peripheral lung lesions has been shown ... does not compromise patients safety. ,Multimodality ... has pushed the diagnostic yield of flexible bronchoscopic procedures ...
... unemployed Argentine Jorge as, picking up a hammer, he goes ... of Madrid. ,Elsewhere in the same hotel, ... but the hotel manager doesn't bat an eyelid. ... the NH Hoteles chain hatched to kill two birds with ...
... from the National Cancer Institute identified Variations in two ... factor for developing lung cancer. The effect of ... that the inflammatory response is important in modulating the ... of the American Association for Cancer Research, is the ...
... found that a variation in two genes related to inflammation, ... ,The study was conducted by a team of researchers led ... University of Texas M. D. Anderson Cancer Center. ... related to inflammation between more than 1,500 lung cancer patients ...
... suicidal thoughts and behaviors appear to be associated ... medication prescriptions among children and adolescents covered by ... are frequently used to treat depression among children ... an increased risk of suicidal thinking and behavior ...
Cached Medicine News:Health News:Dengue Surge in Singapore, Man Prosecuted for Breeding Mosquitoes 2Health News:Combination of Bronchoscopic Techniques is Very Effective for Lung Lesions 2Health News:Smashing Times for Stressed Spaniards 2Health News:Gene Variation Increases the Risk of Lung Cancer 2Health News:Variation in Genes Related to Inflammation Increase Lung Cancer Risk 2Health News:Reduction in Antidepressant Leads to Suicidal Risks 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: